Laboratorios Farmaceuticos Rovi S.A
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Trypti… Read more
Laboratorios Farmaceuticos Rovi S.A - Asset Resilience Ratio
Laboratorios Farmaceuticos Rovi S.A (LABFF) has an Asset Resilience Ratio of 0.17% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2024)
This chart shows how Laboratorios Farmaceuticos Rovi S.A's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Laboratorios Farmaceuticos Rovi S.A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.51 Million | 0.17% |
| Total Liquid Assets | $1.51 Million | 0.17% |
Asset Resilience Insights
- Limited Liquidity: Laboratorios Farmaceuticos Rovi S.A maintains only 0.17% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Laboratorios Farmaceuticos Rovi S.A Industry Peers by Asset Resilience Ratio
Compare Laboratorios Farmaceuticos Rovi S.A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
High Sierra Technologies Inc
PINK:HSTI |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
Annual Asset Resilience Ratio for Laboratorios Farmaceuticos Rovi S.A (2006–2024)
The table below shows the annual Asset Resilience Ratio data for Laboratorios Farmaceuticos Rovi S.A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.03% | $227.00K | $832.02 Million | +0.01pp |
| 2023-12-31 | 0.01% | $113.00K | $799.88 Million | +0.02pp |
| 2022-12-31 | -0.01% | $-65.00K | $878.70 Million | +0.00pp |
| 2021-12-31 | -0.01% | $-65.00K | $732.68 Million | +0.00pp |
| 2020-12-31 | -0.01% | $-65.00K | $574.44 Million | +0.00pp |
| 2019-12-31 | -0.01% | $-65.00K | $511.21 Million | -0.03pp |
| 2018-12-31 | 0.02% | $67.00K | $402.70 Million | +0.00pp |
| 2017-12-31 | 0.02% | $47.00K | $298.38 Million | +0.00pp |
| 2016-12-31 | 0.01% | $32.00K | $287.85 Million | -0.01pp |
| 2015-12-31 | 0.02% | $61.00K | $263.85 Million | 0.00pp |
| 2014-12-31 | 0.02% | $63.00K | $261.32 Million | 0.00pp |
| 2013-12-31 | 0.03% | $63.00K | $235.92 Million | -2.60pp |
| 2011-12-31 | 2.63% | $6.00 Million | $228.07 Million | -9.11pp |
| 2010-12-31 | 11.74% | $25.00 Million | $212.89 Million | +11.74pp |
| 2009-12-31 | 0.00% | $2.00K | $165.91 Million | -0.05pp |
| 2008-12-31 | 0.05% | $72.00K | $135.91 Million | -0.31pp |
| 2006-12-31 | 0.36% | $275.00K | $76.04 Million | -- |